Faeth Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Faeth Therapeutics, Inc. (FTH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -1.30% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-03-28
- Faeth Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -1.30%.
- Faeth Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -1.40%.
- Faeth Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -0.20%.
- Faeth Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was -1.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -1.30% 10-K · filed 2025-03-28 |
| 2023-12-31 | -1.40% 10-K · filed 2025-03-28 |
| 2021-12-31 | -0.20% 10-K · filed 2023-03-29 |
| 2020-12-31 | -1.20% 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |